Key Highlights

  • Vivakor will reactivate the Series A Preferred Stock’s 6% annual dividend for the period ending April 29, 2027.
  • The amendment eliminates a $500,000 obligation owed to Ballengee Holdings, LLC.
  • An aggregate of 3,740,586 restricted common shares will be issued to satisfy unpaid dividend obligations.

Vivakor (NASDAQ: VIVK) reported on July 7, 2026 that it has executed an amendment to its existing debt‑satisfaction and preferred‑stock arrangement. The change restores the 6% annual dividend on its Series A Preferred Stock and initiates the issuance of shares that represent the accrued dividend entitlement.

Amendment Overview

The amendment updates the original agreement dated November 25, 2025, permitting Vivakor to resume the Series A Preferred Stock’s 6% dividend beginning April 30, 2026 and continuing through April 29, 2027. This adjustment enables the company to honor dividend payments that were previously suspended.

Dividend Share Issuance

Under the revised terms, Vivakor will issue a total of 3,740,586 restricted common shares to cover dividend obligations for the April 30, July 31, and October 31, 2026 settlement dates. These shares serve as the compensation for the restored dividend entitlement.

Debt Relief Component

The amendment also incorporates a settlement in which Ballengee Holdings, LLC consents to extinguish a $500,000 promissory note dated May 23, 2024. This action reduces Vivakor’s outstanding liabilities and simplifies its capital structure. These allocations are made in accordance with the terms of the amendment and are intended to satisfy the rights of the Series A Preferred Stock holders or their assignees.

Future True‑Up Provision

The agreement contains a mechanism to address any variances in share counts for the July 31 and October 31 dividend periods. Should the initial allocations prove inaccurate, Vivakor will adjust subsequent issuances to ensure that preferred‑stock investors receive the correct number of shares.

Industry Context

Vivakor operates within the biotechnology sector, focusing on the development of novel therapeutics for neurodegenerative diseases. Restoring the preferred‑stock dividend and resolving outstanding debt are strategic moves aimed at maintaining investor confidence and preserving liquidity as the company advances its clinical programs.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.